Pfizer, Exact Sciences partner on DNA screening test

Aug 24, 2018

Pfizer and Wisconsin-based diagnostics firm, Exact Sciences, announced an agreement through 2021 to drive a DNA screening test for colorectal cancer through expanded sales and marketing efforts.

The companies will invest a combined $48 million, shared equally, next year to market the non-invasive test, Cologuard. Approved in the United States in 2014 to screen adults aged 50 or older at average risk for colorectal cancer, sales of the diagnostic test jumped 78 percent to nearly $103 million in the latest reported quarter.

Exact Sciences will continue to manufacture the test, with Pfizer chipping in with its sales force to boost marketing.

Read the press release

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments